Standard Artesunate Dosage in Combination Therapy
Artesunate is typically used in artemisinin-based combination therapies (ACTs) for uncomplicated Plasmodium falciparum malaria. WHO guidelines recommend a 4 mg/kg body weight dose on day 1, followed by 4 mg/kg on days 2 and 3, combined with a partner drug like amodiaquine, mefloquine, sulfadoxine-pyrimethamine, or lumefantrine.[1][2]
For children under 5 kg, dosing starts at the next weight band to avoid underdosing. Tablets are 50 mg, and rectal formulations exist for severe cases transitioning to combinations.
Dosage by Specific ACT Regimens
- Artesunate-amodiaquine (AS-AQ): Adults 25/100 mg tablets (4 tablets day 1, 4 day 2, 2 day 3); children scaled by weight (e.g., 5-13 kg: 1/2 tablet days 1-2, 1/2 day 3).[2]
- Artesunate-mefloquine (AS-MQ): 4 mg/kg artesunate days 1-3 + 15 mg/kg mefloquine day 2, 10 mg/kg day 3.
- Artesunate-sulfadoxine-pyrimethamine (AS-SP): 4 mg/kg artesunate days 1-3 + single dose SP (25/1.25 mg/kg).[1]
- Artesunate-lumefantrine (AS-L): Similar to artemether-lumefantrine, with artesunate 4 mg/kg days 1-3 + lumefantrine twice daily.[2]
Adjust for hepatic/renal impairment: reduce partner drug if needed, but artesunate remains standard.
Adjustments for Age, Weight, and Severe Malaria
Weight-based bands ensure accuracy:
| Weight (kg) | Day 1 Dose (tablets) | Days 2-3 Dose (tablets) |
|-------------|----------------------|-------------------------|
| <5 | Use next band | Use next band |
| 5-<9 | 1 | 1 |
| 9-<19 | 2 | 2 |
| 19-<35 | 3 | 3 |
| ≥35 | 4 | 4 |[2]
In severe malaria, IV artesunate 2.4 mg/kg at 0, 12, 24 hours, then daily, followed by oral ACT once stable (total 3 days artesunate).[1]
Differences from Monotherapy or Other Indications
Monotherapy is not recommended due to resistance risks; always pair with a partner drug for 3 days.[1] For P. vivax, ACTs clear blood-stage parasites but add primaquine for radicals. No specific pediatric combo adjustments beyond weight; pregnant women use full ACT from second trimester.[2]
Regional Variations and Monitoring
CDC aligns with WHO but notes AS-MQ for chloroquine-resistant areas.[3] Monitor for rare hypersensitivity; complete full course to prevent recrudescence.
[1] WHO Guidelines for Malaria, 2022
[2] Drugs for Neglected Diseases initiative (DNDi) ACT Handbook
[3] CDC Malaria Treatment Tables